Med. praxi. 2011;8(7):310-316 [Interní Med. 2010; 12(10): 470-478]

Long term therapy of osteoporosis

MUDr.Martina Skácelová, prof.MUDr.Pavel Horák, CSc., MUDr.Martin Žurek, Ph.D.

III. interní klinika FN a LF UP Olomouc

Osteoporosis is the most common metabolic bone disease which leads to an increased risk of fractures. Products used in therapy reduce

bone resorption or stimulate bone formation. There are many unanswered questions in the treatment of osteoporosis regarding the

efficacy and safety of long-term therapy, as well as an assessment of its effects or risks associated with the discontinuation of treatment.

Bisphosphonates are potent inhibitors of the bone resorption, their prolonged use increases bone mineral density in the lumbar spine

and hip and reduces the risk of osteoporotic fractures. Discontinuation of bisphosphonates increases the bone resorption and decreased

bone mineral density, the risk of fractures is in the first year after discontinuation reduced, especially at high compliant patients. Discontinuation

of long-term therapy should be individually considered according to the fracture risk assessment and after the evaluation

of potential risks and benefits for the patient.

Keywords: osteoporosis, BMD, vertebral fractures, non-vertebral fractures, bisphosphonates, raloxifen, strontium ranelate

Published: August 1, 2011  Show citation